ANTENGENE-B (06996) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 53.182 million, representing a 12.5% year-on-year decrease. Research and development costs totaled RMB 79.935 million, down 38.91% compared to the same period last year. The adjusted loss for the period was RMB 72.858 million, a significant improvement of 52.25% year-on-year. Loss per share stood at RMB 0.12.

Revenue declined from RMB 60.8 million for the six months ended June 30, 2024, to RMB 53.2 million for the six months ended June 30, 2025, representing a decrease of RMB 7.6 million. In December 2023, Xpovio® (selinexor) was successfully included in the 2023 National Reimbursement Drug List. Due to positive market expectations, this initially drove strong market growth for the six months ended June 30, 2024. Subsequently, market demand gradually returned to rational levels.

Notably, revenue for the six months ended June 30, 2025, increased by RMB 22 million compared to the second half of 2024, reflecting steady revenue growth and stability.